SLS009

SHERIDAN, WYOMING - April 14, 2026 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported full-year 2025 financial results on March 19, 2026, disclosing $71.8 million in cash and cash equivalents as of December 31, 2025, and an additional $42.6 million in warrant exercise proceeds received in Q1 2026. The New York-based biopharmaceutical company advanced two lead oncology candidates simultaneously: galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic in a pivotal Phase 3 trial for acute myeloid leukemia (AML), and SLS009 (tambiciclib), a selective CDK9 inhibitor now enrolling in a Phase 2 first-line AML study. The combined clinical and financial momentum positions SELLAS for multiple potential data readouts before year-end 2026.